Study To Evaluate The Efficacy And Long-Term Adherence Of Spondyloarthropathies(SpA) Patients On Enbrel

Pfizer763 enrolled

Overview

This study is to evaluate local data in Iraqi patients with Spondyloarthropathies on Enbrel treatment with regards to efficacy and adherence using data from the Baghdad Teaching Hospital (Rheumatology Center)

Study Type

OBSERVATIONAL

Enrollment

763

Conditions

Spondyloarthrosis

Interventions

EtanerceptDRUG

Patients with spondyloarthrosis as provided in real world practice

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed SpA patients * 18 years of age and older. * Did not receive previous other biological treatments. * Patients have at least 1 year on Enbrel. Exclusion Criteria: * Had previously used another biological treatments. * Use of etanercept for less than 1 year duration.

Locations (1)

Pfizer

Baghdad, Iraq

Outcomes

Primary Outcomes

Percentage of Participants With 7 Years Adherence to Etanercept

In this outcome measure, percentage of participants who continued etanercept treatment and adhered to the treatment for 7 years were reported.

Time frame: 7 years [from the data retrieved and observed in 1 month of this study]

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.